ストックスクリーナーアプリを入手
4.28
7.81%
0.31
アフターアワーズ：
4.28
前日終値:
$3.97
開ける：
$4.02
24時間の取引高:
2.07M
Relative Volume:
1.10
時価総額：
$404.24M
収益：
$829.00M
当期純損益:
$-399.90M
株価収益率:
-0.9917
EPS:
-4.3159
ネットキャッシュフロー:
$-23.20M
1週間 パフォーマンス:
+12.04%
1か月 パフォーマンス:
-10.83%
6か月 パフォーマンス:
-39.38%
1年 パフォーマンス:
+2.15%
1日の値動き範囲:
$3.99
$4.37
1週間の範囲:
$3.72
$4.37
52週間の値動き範囲:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.28 | 374.96M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
494.04 | 183.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.87 | 129.29B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
566.79 | 44.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.98 | 38.25B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
378.16 | 37.66B | 3.77B | 449.25M | 240.68M | 7.8556 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Statistics Show that Patients Want More Personalized Mental Health Care - KOIN.com
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus - AD HOC NEWS
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock - Yahoo Finance UK
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - TradingView
MYGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Myriad Genetics’ Precise MRD Assay Data Presented at ASCO 2026 Shows Potential for Assessing Treatment Response and Monitoring Recurrence in Cancer Patients - geneonline.com
ASCO study: Myriad blood test flags higher cancer recurrence risk - Stock Titan
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans - Yahoo Finance
MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics (MYGN) Unveils Innovative Prolaris + AI Test for Prostate Cancer - GuruFocus
Myriad Genetics launches Prolaris + AI prostate cancer test - Investing.com UK
Myriad Genetics launches Prolaris + AI prostate cancer test By Investing.com - Investing.com Nigeria
Myriad Genetics Launches Prolaris® + AI - TradingView
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) - marketscreener.com
Myriad Genetics Launches Prolaris Plus AI Test Combining Genomics And Digital Pathology Artificial Intelligence - marketscreener.com
MYGN Technical Analysis & Stock Price Forecast - Intellectia AI
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35 - MSN
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN) - MSN
Myriad Genetics | 5/22/26 - ktnv.com
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships - Traders Union
‘American Idol’ Star Speaks Out on Health Issues 17 Years After Show Appearance - Parade
Myriad Genetics in record sell-off after Q1 miss - MSN
Stocks With 20% Upside: Dollar Tree, Myriad Genetics, Antero Resources AnalysisNews and Statistics - IndexBox
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics, Inc. $MYGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Jackie Tohn joins Myriad Genetics in campaign to expand hereditary cancer test awareness - Traders Union
Myriad Genetics, Inc.Common Stock (NQ: MYGN - FinancialContent
Myriad Genetics and actress Jackie Tohn promote hereditary cancer testing after her BRCA1 gene discovery. - Pluang
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life - markets.businessinsider.com
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing Awareness - Quiver Quantitative
Insider Buying: Paul Bisaro Acquires Shares of Myriad Genetics I - GuruFocus
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Myriad Genetics director Paul Bisaro buys $27,637 in stock By Investing.com - Investing.com Australia
Myriad Genetics director Paul Bisaro buys $27,637 in stock - Investing.com UK
Paul Bisaro (NASDAQ: MYGN) adds 7,500 Myriad Genetics shares - Stock Titan
Myriad Genetics Inc stock (US62855J1043): shares react to Q1 2025 results and updated 2025 guidance - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan - SelectScience
Myriad Genetics unveils ultra-sensitive MRD testing focus at Tokyo oncology summit - Traders Union
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.25%
大文字化:
|
ボリューム (24 時間):